Lakewood-Amedex BiotherapeuticsLABT +2.33%8 3-Year Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100. Among 1,199 Biotechnology companies, Lakewood-Amedex Biotherapeutics ranks worse than 83402.75% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Lakewood-Amedex Biotherapeutics's current 3-Year Share Buyback Ratio was 0.00%.
The historical rank and industry rank for Lakewood-Amedex Biotherapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
During the past 3 years, Lakewood-Amedex Biotherapeutics's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was 0.00%. And the median was 0.00%.
LABT's 3-Year Share Buyback Ratio is not ranked *
in the Biotechnology industry.
Industry Median: -11.9 * Ranked among companies with meaningful 3-Year Share Buyback Ratio only.
Lakewood-Amedex Biotherapeutics (NAS:LABT) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Lakewood-Amedex Biotherapeutics 3-Year Share Buyback Ratio Related Terms
LABT vs APM, NCNA, SNGX: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakewood-Amedex Biotherapeutics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Lakewood-Amedex Biotherapeutics's 3-Year Share Buyback Ratio falls into.
Lakewood-Amedex Biotherapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.00 mean?
Lakewood-Amedex Biotherapeutics (LABT) has a 3-Year Share Buyback Ratio of 0.00 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Lakewood-Amedex Biotherapeutics and its competitors. According to the industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 1199 companies in the Biotechnology industry.
Is Lakewood-Amedex Biotherapeutics' 3-Year Share Buyback Ratio too high?
Lakewood-Amedex Biotherapeutics' current 3-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' 3-Year Share Buyback Ratio compare to APM and NCNA?
According to the Biotechnology industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 1199 companies for 3-Year Share Buyback Ratio. This places Lakewood-Amedex Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current 3-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current 3-Year Share Buyback Ratio of 0.00. The current 3-Year Share Buyback Ratio is 0.00. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current 3-Year Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lakewood-Amedex Biotherapeutics Business Description
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score
Get the complete analysis for LABT
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABT has been successfully added to your 